165 related articles for article (PubMed ID: 32514196)
41. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
[TBL] [Abstract][Full Text] [Related]
42. Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini.
Peresu E; De Graeve D; Heunis JC; Kigozi NG
PLoS One; 2024; 19(4):e0301507. PubMed ID: 38564589
[TBL] [Abstract][Full Text] [Related]
43. Cost of treatment for multidrug-resistant tuberculosis in South Korea.
Kang YA; Choi YJ; Cho YJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Respirology; 2006 Nov; 11(6):793-8. PubMed ID: 17052310
[TBL] [Abstract][Full Text] [Related]
44. Comparing multidrug-resistant tuberculosis patient costs under molecular diagnostic algorithms in South Africa.
du Toit E; Squire SB; Dunbar R; Machekano R; Madan J; Beyers N; Naidoo P
Int J Tuberc Lung Dis; 2015 Aug; 19(8):960-8. PubMed ID: 26162363
[TBL] [Abstract][Full Text] [Related]
45. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
[TBL] [Abstract][Full Text] [Related]
46. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?
Loddenkemper R; Sotgiu G; Mitnick CD
Eur Respir J; 2012 Jul; 40(1):9-11. PubMed ID: 22753833
[No Abstract] [Full Text] [Related]
47. Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.
Reddy KP; Horsburgh CR; Wood R; Fields NF; Girouard MP; Costantini S; Hou T; Freedberg KA; Walensky RP
Ann Am Thorac Soc; 2020 Feb; 17(2):202-211. PubMed ID: 31689133
[No Abstract] [Full Text] [Related]
48. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.
Dowdy DW; van't Hoog A; Shah M; Cobelens F
Int J Tuberc Lung Dis; 2014 Jun; 18(6):647-54. PubMed ID: 24903933
[TBL] [Abstract][Full Text] [Related]
49. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
Marks SM; Mase SR; Morris SB
Clin Infect Dis; 2017 Jun; 64(12):1670-1677. PubMed ID: 28329197
[TBL] [Abstract][Full Text] [Related]
50. Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.
Tsang CA; Shah N; Armstrong LR; Marks SM
Clin Infect Dis; 2020 Feb; 70(5):907-916. PubMed ID: 30944927
[TBL] [Abstract][Full Text] [Related]
51. Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment.
Zwerling A; Dowdy D; von Delft A; Taylor H; Merritt MW
Int J Tuberc Lung Dis; 2017 Nov; 21(11):69-74. PubMed ID: 29025487
[TBL] [Abstract][Full Text] [Related]
52. Latent tuberculosis infection in children: a call for revised treatment guidelines.
Finnell SM; Christenson JC; Downs SM
Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
[TBL] [Abstract][Full Text] [Related]
53. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.
Rouzier VA; Oxlade O; Verduga R; Gresely L; Menzies D
Int J Tuberc Lung Dis; 2010 Oct; 14(10):1316-22. PubMed ID: 20843424
[TBL] [Abstract][Full Text] [Related]
54. Tuberculosis care strategies and their economic consequences for patients: the missing link to end tuberculosis.
Getahun B; Wubie M; Dejenu G; Manyazewal T
Infect Dis Poverty; 2016 Nov; 5(1):93. PubMed ID: 27799063
[TBL] [Abstract][Full Text] [Related]
55. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.
Suárez PG; Floyd K; Portocarrero J; Alarcón E; Rapiti E; Ramos G; Bonilla C; Sabogal I; Aranda I; Dye C; Raviglione M; Espinal MA
Lancet; 2002 Jun; 359(9322):1980-9. PubMed ID: 12076553
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Wolfson LJ; Gibbert J; Wirth D; Diel R
Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
[No Abstract] [Full Text] [Related]
57. [The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis].
Kizkin O; Hacievliyagil SS; Türker G; Günen H
Tuberk Toraks; 2003; 51(4):410-5. PubMed ID: 15143390
[TBL] [Abstract][Full Text] [Related]
58. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis.
Burman WJ; Dalton CB; Cohn DL; Butler JR; Reves RR
Chest; 1997 Jul; 112(1):63-70. PubMed ID: 9228359
[TBL] [Abstract][Full Text] [Related]
59. The costs and outcomes of paediatric tuberculosis treatment at primary healthcare clinics in Johannesburg, South Africa.
Budgell EP; Evans D; Leuner R; Long L; Rosen S
S Afr Med J; 2018 Apr; 108(5):423-431. PubMed ID: 29843858
[TBL] [Abstract][Full Text] [Related]
60. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
Woldeyohannes D; Assefa T; Aman R; Tekalegn Y; Hailemariam Z
PLoS One; 2019; 14(10):e0224025. PubMed ID: 31665154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
